6-bromo-2-chloro-3-methoxypyridine | 850220-78-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-bromo-2-chloro-3-methoxypyridine
• CAS: 850220-78-9
• 化学式: C₆H₅BrClNO
• 分子量: 222.469
• InChiKey: CDTGXQKYYONNKB-UHFFFAOYSA-N

物化性质

• 沸点：
  275.1±35.0 °C(Predicted)
• 密度：
  1.650±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] FUSED LACTAM COMPOUNDS<br/>[FR] COMPOSES DE LACTAME CONDENSE
  申请人：PFIZER JAPAN INC

  公开号：WO2005035523A1

  公开（公告）日：2005-04-21

  This invention provides a compound the formula (I), wherein R1 represents an aryl group having from 6 to 10 ring carbon atoms etc.; R2 represents a hydrogen atom etc., n epresents 0, 1 or 2; said heteroaryl group is unsubstituted or substituted and said ary is substituted by at least one substituer,t selected from the group consisting of substituents a; said substituents a are selected from the group 10 consisting of halogen ate ms, alkyl groups having from 1 to 6 carbon atoms etc.; or a pharmaceutically ac eptable ester of such compound, or a pharmaceutically ac eptable salt thereof. These compou ds are useful for the treatment of disease conditions caused 15 by overactivation of N DA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composi ion comprising the above compound.

  本发明提供了一种具有公式(I)的化合物，其中R1代表一个具有6到10个环碳原子的芳基团等；R2代表一个氢原子等，n代表0、1或2；所说的杂芳基团未取代或取代，所说的芳基至少被一个从由取代基a组成的组中选择的取代基t所取代；所说的取代基a是从由卤素原子、具有1到6个碳原子的烷基团等组成的组中选择的；或者该化合物的药物可接受的酯，或者其药物可接受的盐。这些化合物用于治疗由NDA NR2B受体过度激活引起的疾病状况，如疼痛、中风、创伤性脑损伤、帕金森病、阿尔茨海默病、抑郁症、焦虑症、偏头痛或类似疾病，特别是在哺乳动物中，特别是人类。本发明还提供了一种包含上述化合物的药物组合物。
• FUSED LACTAM COMPOUNDS
  申请人：Pfizer, Inc.

  公开号：EP1673367A1

  公开（公告）日：2006-06-28
• [EN] FARNESOID X RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR FARNÉSOÏDE X ET LEURS UTILISATIONS
  申请人：METACRINE INC

  公开号：WO2020061116A1

  公开（公告）日：2020-03-26

  Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.